- Home
- OLED vs MDGL Comparison
OLED vs MDGL Comparison
Compare OLED & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLED
- MDGL
- Stock Information
- Founded
- OLED 1985
- MDGL 2011
- Country
- OLED United States
- MDGL United States
- Employees
- OLED N/A
- MDGL N/A
- Industry
- OLED Semiconductors
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- OLED Technology
- MDGL Health Care
- Exchange
- OLED Nasdaq
- MDGL Nasdaq
- Market Cap
- OLED 7.2B
- MDGL 7.1B
- IPO Year
- OLED 1992
- MDGL N/A
- Fundamental
- Price
- OLED $113.98
- MDGL $301.66
- Analyst Decision
- OLED Strong Buy
- MDGL Buy
- Analyst Count
- OLED 7
- MDGL 10
- Target Price
- OLED $190.43
- MDGL $354.75
- AVG Volume (30 Days)
- OLED 934.0K
- MDGL 317.2K
- Earning Date
- OLED 05-01-2025
- MDGL 05-06-2025
- Dividend Yield
- OLED 1.54%
- MDGL N/A
- EPS Growth
- OLED 9.67
- MDGL N/A
- EPS
- OLED 4.65
- MDGL N/A
- Revenue
- OLED $647,684,000.00
- MDGL $180,133,000.00
- Revenue This Year
- OLED $6.16
- MDGL $228.41
- Revenue Next Year
- OLED $15.02
- MDGL $73.44
- P/E Ratio
- OLED $24.51
- MDGL N/A
- Revenue Growth
- OLED 12.36
- MDGL N/A
- 52 Week Low
- OLED $103.70
- MDGL $189.00
- 52 Week High
- OLED $237.00
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- OLED 37.54
- MDGL 40.18
- Support Level
- OLED $109.03
- MDGL $292.49
- Resistance Level
- OLED $118.60
- MDGL $330.64
- Average True Range (ATR)
- OLED 9.22
- MDGL 20.56
- MACD
- OLED -0.81
- MDGL -1.56
- Stochastic Oscillator
- OLED 26.16
- MDGL 22.48
About OLED Universal Display Corporation
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. A large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.